High-flow nasal cannula versus standard low-flow nasal cannula during deep sedation in patients undergoing radiofrequency atrial fibrillation catheter ablation: a single-centre randomised controlled trial

Autor: Marloes C. Homberg, Esther A. Bouman, Dominik Linz, Sander M. J. van Kuijk, Bert A. Joosten, Wolfgang F. Buhre

Publikováno v: Trials, Vol 23, Iss 1, Pp 1-12 (2022)

Abstract Background To our knowledge, there are few trials studying the effect of high-flow nasal cannula (HFNC) during deep sedation. Our hypothesis is that high-flow nasal cannula (HFNC) will prevent hypoxemia and desaturation as compared to low-fl

Externí odkaz: https://doaj.org/article/5bf0f802738c48af809082f5a8bcf442

Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT

Autor: Hein J. Verberne, Maartje Piet, Daniela E. Oprea-Lager, R. Jeroen A. van Moorselaar, Joyce M. van Dodewaard-de Jong, Otto S. Hoekstra, Henk M.W. Verheul, Max Dahele, Matthijs C.F. Cysouw, Alfons J.M. van den Eertwegh, Adriaan D. Bins, Esther W. Bouman-Wammes, Ben J. Slotman

Publikováno v: Bouman-Wammes, E W, van Dodewaard-De Jong, J M, Dahele, M, Cysouw, M C F, Hoekstra, O S, van Moorselaar, R J A, Piet, M A H, Verberne, H J, Bins, A D, Verheul, H M W, Slotman, B J, Oprea-Lager, D E & Van den Eertwegh, A J M 2017, ' Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT ', Clinical Genitourinary Cancer, vol. 15, no. 5, pp. e773-e782 . https://doi.org/10.1016/j.clgc.2017.03.009
Clinical Genitourinary Cancer, 15(5), e773-e782. Elsevier
Clinical genitourinary cancer, 15(5), E773-E782. Elsevier

Stereotactic body radiation therapy (SBRT) might postpone the start of androgen deprivation therapy (ADT) in patients with oligometastatic recurrence of hormone-sensitive prostate cancer. We included 43 SBRT-treated patients, and a control cohort of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2838cc154555ba38716376e4efb790b7
https://doi.org/10.1016/j.clgc.2017.03.009

A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial

Autor: Carolien H. Smorenburg, Juleon L.L.M. Coenen, Alfons J.M. van den Eertwegh, Aart Beeker, H. Pieter van den Berg, Winald R. Gerritsen, Walter L. Vervenne, Henk M.W. Verheul, Linda de Munck, Esther W. Bouman-Wammes

Publikováno v: European Journal of Cancer, 90, pp. 1-9
Bouman-Wammes, E W, van den Berg, H P, de Munck, L, Beeker, A, Smorenburg, C H, Vervenne, W L, Coenen, J L L M, Verheul, H M W, Gerritsen, W R & van den Eertwegh, A J M 2018, ' A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial ', European Journal of Cancer, vol. 90, pp. 1-9 . https://doi.org/10.1016/j.ejca.2017.11.021
European Journal of Cancer, 90, 1-9
European Journal of Cancer, 90, 1-9. Pergamon
European journal of cancer (Oxford, England, 90, 1-9. Elsevier Limited

Background Docetaxel is standard first-line chemotherapy for patients with metastatic castration–resistant prostate carcinoma (mCRPC). Docetaxel re-challenge has never been tested in a prospective randomised controlled study. As some studies suppor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46627d79ce31233731263293df40e564
https://hdl.handle.net/2066/183699

A phase 1 trial of cabazitaxel combined with 188Re-hydroxyethylidene diphosphonate in patients with metastatic castration-resistant prostate cancer who progressed on or after a docetaxel-containing treatment the ReCab trial

Autor: Haiko J. Bloemendal, John M. H. de Klerk, Henk M.W. Verheul, Alfons J.M. van den Eertwegh, Esther W. Bouman-Wammes, Joyce M. van Dodewaard-de Jong

Publikováno v: Van Dodewaard-De Jong, J M, Bouman-Wammes, E W, Bloemendal, H J, Verheul, H M W, De Klerk, J M H & Van Den Eertwegh, A J M 2017, ' A phase 1 trial of cabazitaxel combined with 188 Re-hydroxyethylidene diphosphonate in patients with metastatic castration-resistant prostate cancer who progressed on or after a docetaxel-containing treatment the ReCab trial ', Clinical Nuclear Medicine, vol. 42, no. 6, pp. 415-420 . https://doi.org/10.1097/RLU.0000000000001604
Clinical Nuclear Medicine, 42(6), 415-420. Lippincott Williams and Wilkins
Clinical Nuclear Medicine, 42(6), 415. Lippincott Williams and Wilkins

Purpose: In patients with metastatic castration-resistant prostate cancer (mCRPC), bone-seeking radiopharmaceuticals, such as 188Re- hydroxyethylidene diphosphonate (HEDP), are effective for pain palliation and have a marked antitumor effect. Cabazit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e19ee15d9722039068019a6f238dd66
https://research.vumc.nl/en/publications/9df211f1-84b9-4c97-85fc-988a5060bd0f

A phase I trial of cabazitaxel ± rhenium-188-HEDP in patients with metastatic castration resistant prostate cancer who progressed on or after a docetaxel containing treatment

Autor: Esther W. Bouman-Wammes, Joyce M. van Dodewaard-de Jong, Haiko Bloemendal, John M. H. de Klerk, Henk M.W. Verheul, Alfonsus Johannes Maria van den Eertwegh

Publikováno v: Journal of Clinical Oncology. 34:e16508-e16508

e16508Background: In patients with metastatic castration resistant prostate cancer (mCRPC), bone-seeking radiopharmaceuticals such as rhenium-188-HEDP (re-188), are effective for pain palliation an...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7abdfc1f65c17faa488ed603215c971d
https://doi.org/10.1200/jco.2016.34.15_suppl.e16508